Loading
Galena Biopharma
Galena was the company behind NeuVax, a HER2 peptide vaccine meant to stop early breast cancer returning; the phase 3 PRESENT trial was stopped for futility in 2016 and Galena merged into SELLAS.
Also called: Galena Biopharma, Inc.RXi PharmaceuticalsSELLAS Life Sciences
Overview
Galena Biopharma, founded in 2006 and headquartered in Portland, Oregon, developed nelipepimut-S (NeuVax), a HER2-derived E75 peptide vaccine given with GM-CSF to prevent recurrence in node-positive, HER2 low-expressing breast cancer. The phase 3 PRESENT trial was halted for futility in 2016; Galena merged with SELLAS Life Sciences in 2017. Its trials remain on ClinicalTrials.gov under Galena as lead sponsor.
Connected
6Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
cancers
targets
terms
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
galenabiopharma.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add Wikidata ids and Wikipedia links for 80 more companies · diff · file
Sourced, not expert-reviewed